S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:IMGN

ImmunoGen (IMGN) Stock Forecast, Price & News

$15.15
-0.22 (-1.43%)
(As of 06/6/2023 ET)
Compare
Today's Range
$14.89
$15.45
50-Day Range
$3.71
$15.37
52-Week Range
$3.10
$15.59
Volume
4.92 million shs
Average Volume
5.45 million shs
Market Capitalization
$3.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.71

ImmunoGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
1.9% Downside
$14.86 Price Target
Short Interest
Healthy
6.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.53
Upright™ Environmental Score
News Sentiment
0.19mentions of ImmunoGen in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.55) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

704th out of 981 stocks

Pharmaceutical Preparations Industry

337th out of 467 stocks


IMGN stock logo

About ImmunoGen (NASDAQ:IMGN) Stock

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Stock News Headlines

MarketBeat Week in Review – 5/8 - 5/12 (IMGN)
Inflation, bank woes, interest rates, and the debt ceiling led to more of the new normal for equity markets. Here are some of this week's most popular articles
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Piper Sandler Reaffirms Their Buy Rating on ImmunoGen (IMGN)
ImmunoGen (NASDAQ:IMGN) Sets New 12-Month High at $15.45
ImmunoGen (NASDAQ: IMGN)
When Will ImmunoGen, Inc. (NASDAQ:IMGN) Breakeven?
ImmunoGen Sees Unusually High Options Volume (NASDAQ:IMGN)
ImmunoGen: Making A Successful Comeback
See More Headlines

IMGN Price History

IMGN Company Calendar

Last Earnings
4/28/2023
Today
6/06/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
106
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$14.86
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
-9.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-222,930,000.00
Net Margins
-198.88%
Pretax Margin
-197.87%

Debt

Sales & Book Value

Annual Sales
$120.57 million
Book Value
$0.71 per share

Miscellaneous

Free Float
214,608,000
Market Cap
$3.44 billion
Optionable
Optionable
Beta
0.89

Social Links


Key Executives

  • Mark Joseph EnyedyMark Joseph Enyedy
    President, Chief Executive Officer & Director
  • Renee Lentini
    VP-Finance, Chief Financial & Accounting Officer
  • Anna Berkenblit
    Chief Medical Officer & Senior Vice President
  • Michael J. Vasconcelles
    EVP-Research, Development & Medical Affairs
  • Robert Herbst
    Vice President-Technical Operations













IMGN Stock - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings
or view top-rated stocks.

What is ImmunoGen's stock price forecast for 2023?

5 brokers have issued 1 year price targets for ImmunoGen's stock. Their IMGN share price forecasts range from $9.00 to $22.00. On average, they predict the company's share price to reach $14.86 in the next year. This suggests that the stock has a possible downside of 2.3%.
View analysts price targets for IMGN
or view top-rated stocks among Wall Street analysts.

How have IMGN shares performed in 2023?

ImmunoGen's stock was trading at $4.96 at the beginning of the year. Since then, IMGN stock has increased by 206.7% and is now trading at $15.21.
View the best growth stocks for 2023 here
.

Are investors shorting ImmunoGen?

ImmunoGen saw a drop in short interest in May. As of May 15th, there was short interest totaling 15,580,000 shares, a drop of 32.6% from the April 30th total of 23,100,000 shares. Based on an average daily trading volume, of 6,540,000 shares, the short-interest ratio is presently 2.4 days.
View ImmunoGen's Short Interest
.

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IMGN earnings forecast
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Friday, April, 28th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.09. The biotechnology company had revenue of $49.90 million for the quarter, compared to the consensus estimate of $21.63 million. ImmunoGen had a negative trailing twelve-month return on equity of 135.94% and a negative net margin of 198.88%. The business's revenue was up 31.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.10) earnings per share.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2023 earnings guidance on Friday, April, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $108.34 million.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.96%), State Street Corp (7.55%), Wellington Management Group LLP (4.36%), Maverick Capital Ltd. (3.48%), Geode Capital Management LLC (1.79%) and Artisan Partners Limited Partnership (1.41%).
View institutional ownership trends
.

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $15.21.

How much money does ImmunoGen make?

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $3.44 billion and generates $120.57 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does ImmunoGen have?

The company employs 106 workers across the globe.

Does ImmunoGen have any subsidiaries?
The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More
How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.

This page (NASDAQ:IMGN) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -